Clinical Implications of Single Nucleotide Polymorphisms in Diagnosis of Asthma and its Subtypes
- Published on Monday, 17 December 2018 22:49
- Written by Juan Carlos Ivancevich
|Jong-Sook Park,1 Ji-Hye Son,2 Choon-Sik Park,1 and Hun Soo Chang2|
For the past three decades, a large number of genetic studies have been performed to examine genetic variants associated with asthma and its subtypes in hopes of gaining better understanding of the mechanisms underlying disease pathology and to identify genetic biomarkers predictive of disease outcomes. Various methods have been used to achieve these objectives, including linkage analysis, candidate gene polymorphism analysis, and genome-wide association studies (GWAS); however, the degree to which genetic variants contribute to asthma pathogenesis has proven to be much less significant than originally expected. Subsequent application of GWAS to well-defined phenotypes, such as occupational asthma and non-steroidal anti-inflammatory drug exacerbated respiratory diseases, has overcome some of these limitations, although with only partial success. Recently, a combinatorial analysis of single nucleotide polymorphisms (SNPs) identified by GWAS has been used to develop sets of genetic markers able to more accurately stratify asthma subtypes. In this review, we discuss the implications of the identified SNPs in diagnosis of asthma and its subtypes and the progress being made in combinatorial analysis of genetic variants.
Interasma on Twitter
Interasma RT @EAACI_HQ: A promising new diagnostic assay able to identify different phenotypes and degree of #CMA #foodallergy #Allergy_journal https…
Interasma RT @AllergyEaaci: Delayed drug hypersensitivity to bortezomib: desensitization and tolerance to its analogue carfilzomib. Corresponding Aut…